secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001213900-24-042444
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma amends clinical trial service agreement with Eureka to clarify termination payment terms
--------------------------------------------------------------------------------

- Amendment No. 1 to SOW #001 for EB103 anti-CD19 ARTEMIS® clinical trial clarifies pay-on-termination obligations.
- Upon termination, Estrella pays only for achieved milestones, pass-through costs, and third-party commitments before notice.
- Eureka must use commercially reasonable efforts to cancel or reduce such third-party commitments.
- Amendment effective March 4, 2024; filed on May 13, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024042444/0001213900-24-042444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024042444/ea0205983-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer